Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers

Analytical and Quantitative Cytology and Histology

Volumn 19, Issue 4, 1997, Pages 316-328

  Bacus, Sarah ^a   Chin, Dot ^a   Stewart, James ^b   Zelnick, Carolyn ^a   Mahvi, David ^b   Gilchrist, Kennedy ^b  

^a Advanced Cellular Diagnostics Inc   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Breast neoplasms; Computer assisted; Genes; Image analysis; Oncogenes; Predicting factors; Suppressor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIPODOPHYLLOTOXIN DERIVATIVE; ESTROGEN RECEPTOR; FLUOROURACIL; GLYCOPROTEIN P; KI 67 ANTIGEN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PREDNISONE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN; TAXANE DERIVATIVE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; FEMALE; HUMAN; IMAGE ANALYSIS; MULTIDRUG RESISTANCE; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; ONCOGENE PROTEINS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

VINCA;

EID: 0030856596     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Aaronson SA: Growth factors and cancer. Science 1991; 254:1146-1152
2. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in nude mice. J Natl Cancer Inst 1988;80:1605
3. Andrews PA: Mechanisms of acquired resistance to cisplatin. In Anticancer Drug Resistance Advance: Molecular and Clinical Research. Edited by LJ Goldstein, RF Ozols. Boston, Kluwer Academic, 1994, pp 213-244
4. Arteaga CL, Hurd SD, Dugger TC, Winnier AR, Robertson JB: Epidermal growth factor receptor in human breast carcinoma cells: A potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein. Cancer Res 1994;54:4703-1709
5. Bacus SS, Chin D, Ortiz R, Potocki D, Zelnick C: Application of image analysis in the evaluation of cellular prognostic factors in breast cancer. In Compendium on the Computerized Cytology and Histology Laboratory. Edited by GL Wied, PH Bartels, DL Rosenthal, U Schenck, Chicago, Tutorials of Cytology, 1994, pp 143-156
6. Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation alternating the transmembrane domain of p185. Cell 1986;45: 649-657
7. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85:1327-1333
8. HER2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-744
9. Beck WT: Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerase in drug action and resistance. J Natl Cancer Inst 1989;81:83-86
10. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res Treat 1992; 24:85-95
11. Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, BenBaruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y: An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem 1996;271:7620-7629
12. Christen RD, Hom DK, Porter DC, Andrews PA, MacLeod CL, Hafstrom L, Howell SB: Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 1990;86:1632-1640
13. Cole SPC, Bhardwaj J, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multi-drug resistant human lung cancer cell line. Science 1992;258:1650-1654
14. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann FA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptors shares chromosomal location with Neu oncogene. Science 1985;230:1132-1139
15. DeVita VT: Principles of chemotherapy. In Cancer: Principles and Practice of Oncology. Edited by VT DeVita Jr, S Hellman, SA Rosenberg. Fourth edition. Philadelphia, JB Lippincott, 1993, pp 276-292
16. Di Fore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 Is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-182
17. Dickstein B, Valerius EM, Wosikowski, K, Saceda M, Pearson JW, Martin MB, Bates SE: Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 1993;157:110-118
18. Dickstein BM, Wosikowski K, Bates S: Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 1995;110:205-211
19. Friedrich K, Dimmer V, Haroske G, Lossnitzer A, Kasper M, Theissig F, Kunze KD: Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers. Pathol Res Pract 1995;191:1114-1121
20. Fruehauf JP, Bosanquet AG: In vitro determination of drug response: A discussion of clinical applications. Princ Pract Oncol 1993;7:1-16
21. Gasparini G, Barbareschi M, Doglioni C: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res 1995;1:189-198
22. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993;85:1206-1219
23. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993;53:747-754
24. Gregorczyk S, Kang Y, Brandt D, Kolm P, Singer G, Perry RR: p-Glycoprotein expression as a predictor of breast cancer recurrence. Ann Surg Oncol 1996;3:8-14
25. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstram CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neveille AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn HJ: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10:1049-1056
26. Hancock NC, Langton BC, Chan T, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-Diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1996;51:4575-4580
27. Hanks SK: Eukaryotic protein kinases. Curr Opin Struct Biol 1991;1:369-383
28. Hayes DF: Should we treat HER, too? J Clin Oncol 1996; 14:697-699
29. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992;84:1109-1114
30. Isonishi S, Hom DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A, Howell SB: Expression of the c-Ha-ras oncogene in mouse 3T3 cells induces resistance to cisplatin. Cancer Res 1991;51:5903-5909
31. Lipponen HJ, Aaltomaa S, Syrjanen S, Syrjanen K: c-erbB-2 Oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res 1993;13: 1147-1152
32. Kallioniema OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-655
33. Kilhara A, Pastan I: Small chimeric toxins containing only transforming growth factor o and domain III of pseudomonas exotoxin with good antitumor activity in mice. Cancer Res 1994;54:5154-5159
34. Kovach J, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;13:1093-1096
35. Kraus MH, Fedi P, Starks V, Muraro R, Aaronson SA: Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 1993;90: 2900-2904
36. LeMaistre CF, Mencghetti C, Howes L, Osborne CK: Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 1994;32:97-103
37. Lowe SW, Bodis S, McClatchey A, Remington L, Ryley HE, Fisher DR, Housman DE, Jacks T: p53 Status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810
38. McGuire WL, Tandon AK, Allred C, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-1015
39. Meyers MB, Merluzzi VJ, Spengler BA, Biedler JL: Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc Natl Acad Sci USA 1986;83:5521-5525
40. Meyers MB, Yu P, Mendelsohn J: Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin-D resistant Chinese hamster lung cells. Biochem Pharmacol 1993;46:1841-1848
41. Moll UM, Riou G, Levine AJ: Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992;89:7262-7266
42. Morrow CS, Cowan K: Glutathione S-transferases and drug resistance. Cancer Cells 1990;2:15
43. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266
44. National Institute of Health Consensus Development Conference: Steroid Receptors in Breast Cancer. Second volume, no 6. Bethesda, Maryland, NIH 1979
45. Niimi S, Yokoyama S, Terashima Y, Saigo N: Resistance to anticancer drugs in NIH3T3 cells transferred with c-myc and/or c-H-ras genes. Br J Cancer 1991;63:237-241
46. O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA: Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 1990;26:1035-1038
47. Page DL, Anderson TJ, Goi Sakamoto: Infiltrating carcinoma: Major histological types. In Diagnostic Histopathology of the Breast. Edinburgh, Churchill Livingstone, 1990, pp 193-234
48. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85: 1419-1423
49. Pastan I, Gottesman MM: Multidrug resistance. Annu Rev Med 1991;42:277-286
50. Pastan I, Fitzgerald D: Recombinant toxins for cancer treatment. Science 1991;254:1173-1177
51. Pegram M, Lipton A, Pietras R: Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer (abstr). Proc of the American Society for Clinical Oncology. ASCO, 1995, p 106
52. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos, L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cell. Oncogene 1995;10:2435-2446
53. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ: Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-1938
54. erbB4. Nature 1993;366:473-475
55. Querzoli P, Ferretti S, Albonico G, Magri E, Scapoli D, IndelIi M, Nenci T: Application of quantitative analysis to biologic profile evaluation in breast cancer. Cancer 1995;76:2510-2517
56. Roninson IB, Pantel MC, Lee I, Noonan KE, Chen CJ, Choi K, Chin JE, Kaplan R, Tsuruo T: Molecular mechanism and diagnostics of multidrug resistance in human tumor cells. In Cancer Cells: Molecular Diagnostics of Human Cancer. Cold Spring Harbor, Maine, Cold Spring Harbor Laboratory, 1989, pp 81-86
57. Schimke RT: Gene amplification in cultured cells. Cell 1984;37:705-713
58. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of the HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936-1942
59. Siegall CB, Bacus SS, Cohen BD, Plowman GD, Mixan B, Chace D, Chin DM, Goetze A, Green JM, Hellstrom I, Hellstrom KE, Fell HP: HER-4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J Biol Chem 1995;270:7625-7630
60. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire RL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
61. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SC, Keith DE, Levin WJ, Stuart SG, Udore J, Ullrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-712
62. Sliwkowski M, Schaefer G, Akita R, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway III KL: Coexpression of erbB2 and erbB3 reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994; 269:14661-14665
63. Smith PJ: DNA topoisomerase dysfunction: A new goal for antitumor chemotherapy. Bioessays 1990;12:167-172
64. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-855
65. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellstrom I, Hellstrom KE: Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993;261:212-215
66. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212
67. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2 (Neu) or c-myc protooncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987;1:423-430
68. Venter DJ, Tsui NL, Kummar S, Gullick WJ: Overexpression of the cerbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlated with gene amplification. Lancet 1987;2:67-72
69. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996;2:72-79
70. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Home CHW: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118-121
71. Yarden Y, Ullrich A: Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-448